Clinical trial
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
NCT00161668 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161668 |
|---|---|
| Title | Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care |
| Official title | Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Mylotarg |
| Enrollment | 500 |
| Start date | Oct 1, 2001 |
| First posted | Sep 12, 2005 |
| Last update posted | Mar 15, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: